Eyepoint Non Current Assets Total from 2010 to 2025
| EYPT Stock | USD 14.83 0.04 0.27% |
Non Current Assets Total | First Reported 2003-06-30 | Previous Quarter 35.9 M | Current Value 35.6 M | Quarterly Volatility 31 M |
Check Eyepoint Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyepoint Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 13.3 K or Total Revenue of 45.4 M, as well as many indicators such as Price To Sales Ratio of 9.21, Dividend Yield of 0.0 or PTB Ratio of 1.18. Eyepoint financial statements analysis is a perfect complement when working with Eyepoint Pharmaceuticals Valuation or Volatility modules.
Eyepoint | Non Current Assets Total | Build AI portfolio with Eyepoint Stock |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.